Are you attending the @BIOConvention 2024? and looking for biopharma partners? Then collect your copy of our June edition, located on the @SpringerNature booth #3940. Packed with companies looking to partner in #infectiousdiseases and #womenshealth amongst others.
Biopharma Dealmakers
Biotechnology Research
Nurturing biopharma partnerships. A Nature Research publication.
About us
Biopharma Dealmakers – a Nature Research publication – showcases active partnering companies and their opportunities across the biopharma industry.
- Website
-
https://www.nature.com/biopharmdeal
External link for Biopharma Dealmakers
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Founded
- 2007
Updates
-
By combining complementary capabilities with biopharma partners, GSK knows that dealmaking offers a competitive advantage in drug discovery. #AdFeature with GSK
-
Discover how GSK is committed to being the partner of choice, with the agility to quickly evaluate deals and the scale to rapidly advance drug development. #AdFeature with GSK
Evaluating deals to rapidly advance drug development
nature.com
-
Knowing the best science doesn’t happen in isolation, GSK has more than 100 active alliances across biotech and academia. Could you be next? #AdFeature with GSK
Could you be GSK's next partner?
nature.com
-
Read our March issue....with active companies focused on the prevention and treatment of oncology, this edition also includes a landscape piece on the resurgence of second-generation #radiopharmaceuticals with the help of Back Bay Life Science Advisors https://lnkd.in/et9abEsK #oncology #radiotherapy #antifibrotic #breastcancer #solidtumors #bloodtests #immunotherapy #RNA https://lnkd.in/ePtTAPFs
-
-
Our molecular diagnostics and precision medicine collection is now live! Discover new companies working in the field, and read our landscape feature that explores how biopharma companies are partnering with pioneers of genome-editing technologies. #precisionmedicine #genomeediting #crispr #diagnostics https://lnkd.in/eXC3DsuF
What’s next for molecular diagnostics and precision medicine?
nature.com
-
Our final issue of 2023 is here, in this packed edition we provide company profiles and landscape features focused on combatting aging, #CNS diseases, #rna , and cell/gene therapies. We also review the top 20 highest-value deals of 2023. Take a look! https://lnkd.in/eaZec8V5 #genetherapy #geneediting #CNS #aging DealForma
Biopharma Dealmakers - In this issue...
nature.com
-
Targeting eye diseases to flu, discover Ocugen’s novel platforms: modifier gene therapy; regenerative cell therapy; and an inhaled mucosal vaccine platform. #AdFeature with Ocugen https://lnkd.in/efR6dgSz
Technologies targeting eye diseases and flu
nature.com
-
Explore how IBM’s Accelerated Discovery initiative is building new AI-driven applications and tools to help researchers pursue molecular discovery. #AdFeature with IBM https://lnkd.in/e5phAn5H
Empowering researchers to rapidly discover drugs
nature.com
-
Discover CellGenTech’s pioneering approach of using adipocytes suitable for gene therapy—for ex vivo applications in a range of diseases caused by single-gene defects. #AdFeature with Cellgen https://lnkd.in/e7t26NYa
Harnessing adipocytes for gene therapy
nature.com